Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...
Background and Clinical Significance: Adults suffering from cerebellar metastases are often at high risk for rapid deterioration of their neurological status because the posteri...
Type B aortic dissection (TBAD) requires management tailored to the disease phase and clinical presentation, with the subacute period representing a favorable window for endovas...
Colorectal cancer (CRC) represents a significant global health burden, ranking as the third most frequently diagnosed malignancy worldwide. Emerging evidence has established a c...
Introduction In some cases, endovascular abdominal aortic repair (EVAR) may be hampered by specific anatomical features, the so-called “hostile neck.” Aim To analyse the results...
Abstract Pulmonary arterial hypertension (PAH) is a complex, chronic-progressive, debilitating condition with a multifactorial etiology and a severe prognosis. Remodeling of the...